Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 94

1.

Prospective multicenter clinical trial of Chinese herbal formula JZQG (Jiangzhuoqinggan) for hypertension.

Tong XL, Lian FM, Zhou Q, Xu LP, Ji HY, Xu GC, Hu YH, Zhao LH, Xia L, Wang J, Chen XY, Chan MH, Zhang LL, Gao W, Zhen Z, Zhou SP, Chang B.

Am J Chin Med. 2013;41(1):33-42. doi: 10.1142/S0192415X13500031.

PMID:
23336505
2.

Clinical study of western medicine combined with Chinese medicine based on syndrome differentiation in the patients with polarized hypertension.

Chen SL, Liu XY, Xu WM, Mei WY, Chen XL.

Chin J Integr Med. 2012 Oct;18(10):746-51. doi: 10.1007/s11655-012-1231-7. Epub 2012 Sep 11.

PMID:
22965699
3.

Aliskiren reduces blood pressure and suppresses plasma renin activity in combination with a thiazide diuretic, an angiotensin-converting enzyme inhibitor, or an angiotensin receptor blocker.

O'Brien E, Barton J, Nussberger J, Mulcahy D, Jensen C, Dicker P, Stanton A.

Hypertension. 2007 Feb;49(2):276-84. Epub 2006 Dec 11.

4.
5.

Antihypertensive efficacy of Irbesartan/HCTZ in men and women with the metabolic syndrome and type 2 diabetes.

Sowers JR, Neutel JM, Saunders E, Bakris GL, Cushman WC, Ferdinand KC, Ofili EO, Weber MA; INCLUSIVE Investigators..

J Clin Hypertens (Greenwich). 2006 Jul;8(7):470-80.

6.

A multicenter, randomized, double-blind comparison of the efficacy and safety of irbesartan and enalapril in adults with mild to moderate essential hypertension, as assessed by ambulatory blood pressure monitoring: the MAPAVEL Study (Monitorización Ambulatoria Presión Arterial APROVEL).

Coca A, Calvo C, García-Puig J, Gil-Extremera B, Aguilera MT, de la Sierra A, Martín-Hidalgo A, Marín R; MAPAVEL Investigators (Monitorizacíon Ambulatoria Presión Arterial APROVEL)..

Clin Ther. 2002 Jan;24(1):126-38.

PMID:
11833827
8.

Irbesartan/hydrochlorothiazide for the treatment of isolated systolic hypertension: a subgroup analysis of the INCLUSIVE trial.

Chrysant SG, Neutel JM, Ferdinand KC; INCLUSIVE investigators..

J Natl Med Assoc. 2009 Apr;101(4):300-7.

PMID:
19397219
9.
10.

Comparison of monotherapy with irbesartan 150 mg or amlodipine 5 mg for treatment of mild-to-moderate hypertension.

Neutel JM, Germino FW, Smith D.

J Renin Angiotensin Aldosterone Syst. 2005 Sep;6(2):84-9.

PMID:
16470487
11.
12.

Irbesartan, an angiotensin receptor blocker, exhibits metabolic, anti-inflammatory and antioxidative effects in patients with high-risk hypertension.

Taguchi I, Toyoda S, Takano K, Arikawa T, Kikuchi M, Ogawa M, Abe S, Node K, Inoue T.

Hypertens Res. 2013 Jul;36(7):608-13. doi: 10.1038/hr.2013.3. Epub 2013 Feb 21.

PMID:
23425956
13.

Randomized, double-blind comparison of irbesartan and enalapril for treatment of mild to moderate hypertension.

Chiou KR, Chen CH, Ding PY, Chen YT, Ting CT, Huang JL, Chiang AH, Liu CP, Tseng CJ, Chao CT, Chang MS.

Zhonghua Yi Xue Za Zhi (Taipei). 2000 May;63(5):368-76.

PMID:
10862446
14.

BP goal achievement in patients with uncontrolled hypertension : results of the treat-to-target post-marketing survey with irbesartan.

Schrader J, Bramlage P, Lüders S, Thoenes M, Schirmer A, Paar DW.

Clin Drug Investig. 2007;27(11):783-96.

PMID:
17914897
16.

A comparison of the efficacy and safety of irbesartan/HCTZ combination therapy with irbesartan and HCTZ monotherapy in the treatment of moderate hypertension.

Neutel JM, Franklin SS, Lapuerta P, Bhaumik A, Ptaszynska A.

J Hum Hypertens. 2008 Apr;22(4):266-74. Epub 2007 Oct 11.

PMID:
17928878
17.

Effects of Chinese herbal medicine Yiqi Huaju Formula on hypertensive patients with metabolic syndrome: a randomized, placebo-controlled trial.

Chen Y, Fu DY, Chen Y, He YM, Fu XD, Xu YQ, Liu Y, Feng XT, Zhang T, Wang WJ.

J Integr Med. 2013 May;11(3):184-94. doi: 10.3736/jintegrmed2013031.

PMID:
23743162
18.

Supplemental Content

Support Center